Printer Friendly Printed from http://www.researchandmarkets.com/reports/316926 The Market for Pharmaceuticals in Brazil, Russia, India & China 2008 Description: Evaluate the status, opportunities and threats for pharmaceutical companies in Brazil, Russia, India and China now and in the future. Market forecasts to 2013 are provided, plus free quarterly-updated market outlook reports on each country, keeping you up to date with developments for a full year. Many are concerned that a potential global economic downturn could blunt the rapid growth in the BRIC countries. Is this a time of exciting opportunity or commercial danger for pharmaceutical manufacturers? This report separates the fact from the fiction and is essential in making sound, impartial business judgements. This insightful report provides: - 5-year forecasts to 2013 and market valuations for each market - A detailed analysis of the health structure, funding, service and outlook - Quarterly updated reports of key developments in the market These leading emerging and rapidly-growing economies represented a total market of 2.76 billion people and a combined GDP of US$6.1 trillion in 2007. But where do commercial opportunities exist for pharmaceutical companies now, and what are the future prospects? Putting things in perspective The BRIC countries’ pharmaceutical markets are currently valued at US$54.9 billion. This is a large sum of money, but is collectively lower than found in leading markets such as the USA and Japan. Growth rates, ranging from 5% in Brazil to 15% in Russia are impressive, but the low starting point – along with a range of other operational issues – means companies must be targeted in the opportunities they pursue. Opportunities do exist There are, of course, wide regional differences in expenditure levels within the BRIC countries, far more so than in developed countries where health systems have evolved to provide a more uniform level of coverage. All four countries have a relatively wealthy urban population with a far greater spending power than their respective national average. In the case of China and India, these urban populations have grown rapidly, and number hundreds of millions. The challenge for these countries is to extend this level of wealth to the rest of the population, in order that better levels of healthcare become affordable. A long haul This is evolution not revolution, and change will be incremental. Short-term opportunities exist in meeting the health demands of the burgeoning middle classes, and future prospects are bright, where steady growth in BRIC markets will erode commercial differences with the established markets in North America, Japan and Europe. Current and accurate decision support information is vital For each country there is a comprehensive examination of the market for pharmaceuticals which covers all aspects of the operating environment from the regulatory situation through health provision/expenditure to domestic production. Importantly, each market evaluation includes 5-year growth forecasts and SWOT analysis. An additional benefit - at no extra cost – is that concise quarterly-updated outlook reports are included in the price. Contents: COUNTRY ANALYSIS Key National Indicators - Economic, population, and health data forecast to 2013 Healthcare system - Organisation & administration - Health expenditure - Expenditure by source of funding and type - Hospital services - Hospital data such as beds by type, region, specialty, patient admissions and surgical procedures - Outpatient care - Medical personnel - Data on healthcare professionals covering such areas as doctors by specialty, nursing staff and dentists Accessing the pharmaceutical market - Regulatory environment - Distribution guide and trade fair information - Domestic production Contact details - For healthcare organisations and trade associations QUARTERLY-UPDATED REPORTS INCLUDED! Buyers of this report will receive, for each market, 4 quarterly reports covering: - Current market size - Unique 5-year market projections to 2013 - Market outlook & structure - Comment & rating - Import and export data - Market developments, covering recent and impending developments with respect to key issues such as regulation, health facilities, and funding Summary: Highlights from the Report BRAZIL Due to the depreciation of the US dollar, the Brazilian pharmaceutical market is experiencing high growth in dollar values. The Brazilian pharmacy sector was valued at US$9.8 billion in 2006, well ahead of the pharmacy sector in Mexico, valued at US$9.6 billion. Drug prices continue to increase in spite of generics competition. Excluding ICMS and other taxes applicable to drugs, FEBRAFARMA estimated the annual pharmaceutical market at US$10.9 billion and 1.7 billion units in 2006. Including ICMS and other taxes, Espicom estimates the market to reach around US$13.6 billion in 2007, equal to US$72 per capita. The generics sector is dominated by local producers, restricting the market entry for foreign producers. In 2006, generics sales amounted to US$1.1 billion, equal to 10.7% of the overall pharmacy sector. Generics sales will continue to outperform the pharmacy sector, fuelled by generics production of oral contraceptives & hormones and blockbusters losing their patents. RUSSIA In 2007, the Russian pharmaceutical market is estimated at US$8.3 billion, equal to around US$59 per capita. The market size is almost three times larger than the Czech Republic. In per capita terms, the market is similar to Romania. The market is split between imported products and cheap locally-produced generics. Imports account for around 69% of the pharmaceutical market. According to the Ministry of Health and Social Development, approximately 60% of imported drugs were generics in 2006. In 2005, new rules governing the supply of drugs to vulnerable population groups came into force. Patients have to choose between receiving a package of benefits including free medicines or accepting a sum of R513 each month. The government initially allocated US$1.7 billion for the programme, but this fell by 41% in 2006, due to half of the population opting out in favour of the cash equivalent. The budget for 2007 is R34.9 billion (US$1.3 billion), although this is unlikely to cover costs. INDIA With a population of over one billion, the pharmaceutical market in India has considerable potential. Espicom’s market projections assume stable market growth of around 8.4% per year, putting the market at US$15.6 billion by 2012. It should be noted, however, that if calls for an end to drug price controls come to fruition, short-term market growth is likely to be much higher. As India develops, the disease profile of the country is changing. Traditional infectious diseases such as smallpox have been eradicated and the number of cases of vaccine preventable conditions has also been greatly reduced. Along with life expectancy, however, the prevalence of western style diseases has been increasing. There are around 700,000 new cases of cancer each year and a total of around 2.5 million cases. Around two thirds of cases are in an advanced stage at the time of detection. The majority of these are smoking related cancers. CHINA The pharmaceutical market in China (excluding Hong Kong) is estimated at US$22.6 billion in 2007, an increase of around 8.5% over the previous year. The figure is distorted, however, by the presence of traditional Chinese medicines (TCMs). The TCM market is estimated to be worth around US$5-6 billion. The size of the market for western-style pharmaceuticals, therefore, can be reckoned at around US$17.0 billion, equal to around US$13 per capita. This makes China one of the largest markets in the world, and second only to Japan in Asia. Per capita spending on pharmaceuticals remains among the lowest in the world, however, and is broadly comparable with India. The Chinese pharmaceutical market has shown impressive growth in recent years, in tandem with the country’s rapid economic expansion. The influx of foreign multinationals in recent years has offered continued investment, and production plants and R&D facilities are being expanded all the time. Improvements in regulatory practices are making the ability to sell imported products quicker and easier, while the lowering of tariffs on imported goods and an increase in transparency of legislation has made a notoriously hard-to-penetrate market a more attractive proposition for overseas companies. Imports continue to rise, with 2005 seeing an increase of 21.8%. Recent government price cuts, particularly pertaining to the burgeoning category of antibiotics are likely to affect some companies, and although an anticipated price war is likely to have an effect on the market, the industry as a whole will become more competitive. Ordering: Order Online - visit http://www.researchandmarkets.com/reports/316926 Order by Fax - using the order form below Order By Post - print the order form below and send to Research and Markets, Guinness Centre, Taylors Lane, Dublin 8, Ireland. Page 1 of 2 Printed 28/08/2008 12:29:04 Fax Order Form To place an order via fax simply print this form, fill in the information below and fax the completed form to the number at the bottom of this page. If you have any questions please email help@researchandmarkets.com Order information Please verify that the product information is correct and select the format you require. Product Name: The Market for Pharmaceuticals in Brazil, Russia, India & China 2008 Web Address: http://www.researchandmarkets.com/reports/316926 Office Code: OCHGKPPPTUR Report formats Please enter the quantity of the report format you require. Format Quantity Price Electronic (PDF) - Single User €1,945.00 Hard Copy €1,945.00 + EUR€ 50.00 Shipping/Handling * * Shipping/Handling is only charged once per order. Contact information Please enter all the information below in BLOCK CAPITALS. First Name:   Last Name:   Email Address: Job Title: Organisation: Address: City: Postal/Zip Code: Country: Phone Number: Fax Number: Please fax this form to: (646)607-1907 or (646)964-6609 - From USA +353-1-481-1716 or +353-1-653-1571 - From Rest of World Page 2 of 2 Printed 28/08/2008 12:29:04 Payment information Please indicate the payment method you would like to use by selecting the appropriate box.  Pay by Credit Card: American Express Diners Club Master Card Visa Cardholder Name: Expiry Date: / Card Number: CVV Security Code: Issue Date: /   (Diners Club only)  Pay by Check: Please post the check, accompanied by this form, to: Research and Markets, Guinness Centre, Taylors Lane, Dublin 8, Ireland.  Pay by Wire Transfer: Please transfer funds to: Account number: 83313083 Sort code: 98-53-30 Swift code: ULSBIE2D IBAN number: IE78ULSB98533083313083 Bank Address: Ulster Bank, 27-35 Main St, Blackrock, Co. Dublin, Ireland. If you have a Marketing Code please enter it below: Marketing Code: Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp Please fax this form to: (646)607-1907 or (646)964-6609 - From USA +353-1-481-1716 or +353-1-653-1571 - From Rest of World